Shares of Vertex Pharmaceuticals rose after Journavx, the company’s oral non-opioid pain medication, received Food and Drug ...
The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' drug to treat acute pain, the health regulator ...
The Vertex drug is a milestone after a long history of unsuccessful efforts to develop painkillers without the addictive ...
Vertex Pharmaceuticals won FDA approval for its non-opioid painkiller Journavx. Vertex stock jumped in late trading.
U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated ...
Vertex Pharmaceuticals Inc. (VRTX) has secured FDA approval for Suzetrigine, an oral, non-opioid, highly selective NaV1.8 pain signal ...
Vertex Pharmaceuticals Incorporated announced that the U.S. Food and Drug Administration has approved JOURNAVX, an oral, non-opioid, highly selective NaV1.8 pain signal inhibitor ...
The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...
The FDA approved Vertex Pharmaceuticals’ Journavx, a new non-opioid pain pill for short-term pain. While safer than opioids, ...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVXâ„¢ (suzetrigin ...
Despite high demand for an option like Journavx, doctors fear the drug’s price could be a major hangup for insurers, ...